IUSM Alzheimer's Disease Drug Discovery Center

IUSM 阿尔茨海默病药物研发中心

• 批准号: 10017136
• 负责人: Bruce T Lamb
• 金额: $ 745.74万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10017136
• 关键词: Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease model; Amyloid beta-Protein; Animal Disease Models; Basic Science; Biological Markers; Biology; Brain; Cause of Death; Clinical Research; Clinical Sciences; Clinical Trials Design; Communities; Custom; Data; Dimensions; Disease; Drug Targeting; Elements; Ensure; Feasibility Studies; Foundations; Generations; Genetic; Goals; Human Pathology; Immunization; Indiana; Institutes; Intervention; Investments; Lead; Methods; Mission; Modality; Modeling; Molecular; Nerve Degeneration; Neuroimmune; Pathway interactions; Patients; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Postdoctoral Fellow; Presenile Alzheimer Dementia; Probability; Process; Research; Research Personnel; Resources; Risk; Science; Scientist; Technology; Testing; Therapeutic; Time; Toxicology; Translating; Translational Research; United States; United States National Institutes of Health; Universities; Validation; Work; abeta accumulation; base; beta secretase; data access; data sharing; design; disability; drug candidate; drug development; drug discovery; experimental study; flexibility; gamma secretase; human disease; inhibitor/antagonist; innovation; insight; medical schools; novel; open data; physical property; pre-clinical; sharing platform; success; translational study; validation studies

The strategic goal of the Indiana University School of Medicine Alzheimer’s Disease Drug Discovery (ADDD) Center is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s disease (AD) target hypotheses (beyond Ab) with the goal of generating new classes of potential therapeutics. Specifically, the ADDD CENTER will establish itself as a strategic and operational partner for the NIA AMP-AD and MODEL-AD initiatives. By design, this will provide drug discovery capability to bridge the foundational work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics and translational biomarkers (MODEL-AD). To accomplish the mission of the ADDD CENTER, we have assembled a world-class team of scientists and capabilities from Indiana University, Purdue University, and the Indiana Clinical and Translational Sciences Institute (CTSI). This team has considerable expertise in Alzheimer’s disease biology, CNS pharmaceutical drug discovery and development, and scientific excellence in the core discovery technologies that will drive the ADDD CENTER’s contributions and deliverables. A key advantage and differentiated strength of the proposed ADDD CENTER is the primary scientific coordination and administration through the Indiana University School of Medicine. Specifically, this concentrates a strong and long-standing commitment to neurodegenerative research through co-presence with the NIA-supported Indiana Alzheimer’s Disease Center under the direction of Dr. Andy Saykin, the MODEL-AD consortium under the direction of Dr. Bruce Lamb, and the Longitudinal Early Onset Alzheimer’s Disease (LEAD) study under the direction of Dr. Liana Apostolova. The Specific Aims of the ADDD CENTER are: 1. Create a dynamic portfolio of well-characterized AD drug discovery targets representing novel intervention hypotheses that capitalize on significant investments in basic research and emerging disease understanding. 2. Perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. 3. Create high-quality and well-characterized lead molecules for prioritized targets that meet rigorous milestone criteria and are valued opportunities for further translational investment. 4. Create a robust and flexible data sharing platform to enable global researchers with data and target enablement packages to expand on the work of the ADDD CENTER.

印第安纳大学医学院阿尔茨海默氏病药物发现（ADDD）中心的战略目标是整合早期药物发现的复杂能力，并为对新兴阿尔茨海默氏病（AD）目标假设（Beyonder AB）的更广泛研究做出了贡献，目的是将新的潜在治疗类别的新类别进行。具体而言，ADDD中心将成为NIA AMP-AD和Model-AD计划的战略和运营合作伙伴。根据设计，这将提供药物发现的能力，以弥合目标发现（AMP-AD）的基础工作，其新发现的铅分子在基于人类病理学，遗传学和翻译生物标志物（Model-AD）的AD动物模型中表征。为了完成ADDD中心的任务，我们组建了印第安纳大学，普渡大学和印第安纳州临床和转化科学学院（CTSI）的世界一流的科学家和能力团队。该团队考虑了阿尔茨海默氏病生物学，中枢神经系统药物发现和开发的专业知识，以及核心发现技术的科学卓越，这些技术将推动ADDD中心的贡献和可交付成果。拟议的ADDD中心的主要优势和差异化的优势是通过印第安纳大学医学院的主要科学协调和管理。具体而言，这将通过与NIA支持的印第安纳州阿尔茨海默氏病的共同培训在Andy Saykin博士的指导下，在Bruce Lamb博士的指导下与纵向早期的Arzheimer病（主管）研究APPOST的指导下，这将集中在神经退行性研究中的坚定而长期的承诺。 ADDD中心的具体目的是：1。创建一个充分表征的AD药物发现目标组合，代表了新的干预假设，这些假设利用了基础研究和新兴疾病理解的大量投资。 2.执行先进的临床前目标验证和支持研究，以优先考虑治疗发现的最佳机会。 3.为符合严格里程碑标准的优先目标创建高质量且良好的铅分子，并且是进一步转化投资的重要机会。 4.创建一个强大而灵活的数据共享平台，以使全球研究人员使用数据和目标启用软件包来扩展ADDD中心的工作。